Kevin Brown

Jun 27, 2024 | bmjopenrespres.bmj.com | Toby Maher |Michael Kreuter |David Lederer |Kevin Brown

Interstitial lung disease Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2) Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.

Jun 27, 2024 | bmjopenrespres.bmj.com | Kevin Flaherty |Kevin Brown |Athol U Wells |Emmanuelle Clerisme-Beaty

The PF-ILD trial (1199.247, NCT02999178) is a multicentre, prospective, randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of nintedanib in patients with progressive fibrosing lung disease over 52 weeks. The study is conducted at specialised referral centres experienced in ILD management in approximately 15 countries of the Americas, Europe and Asia.

Jun 5, 2024 | bmj.com | Kevin Schwartz |Jennifer Shuldiner |Bradley J. Langford |Kevin Brown

Research BMJ 2024; 385 doi: https://doi.org/10.1136/bmj-2024-079329 Cite this as: BMJ 2024;385:e079329 Linked Editorial Antimicrobial stewardship Kevin L Schwartz, assistant professor1 2 3 4, Jennifer Shuldiner, doctoral student5 6, Bradley J Langford, assistant professor1 3, Kevin A Brown, associate professor1 2 3, Susan E Schultz, senior analyst2, Valerie Leung, pharmacist1 7, Nick Daneman, professor1 2 6 8, Mina Tadrous, assistant professor2 5 9, Holly O Witteman, associate professor10 11,...